4 completed, 4 terminated, 2 active not recruiting. 4 Phase 1, 2 Phase 2, 1 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 3, Terminated 1 |
| Phase 2 | 2 | Active not recruiting 1, Terminated 1 |
| Not applicable | 1 | Terminated 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Fallopian Tube Adenocarcinoma: new trials by email Literature Review of Fallopian Tube Adenocarcinoma trials Research Report on Fallopian Tube Adenocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| FT516 and IL2 With Enoblituzumab for Ovarian Cancer IP FT516, Enoblituzumab, IL-2 - Ovarian Cancer, Fallopian Tube Adenocarcinoma | Phase 1 | Completed | Masonic Cancer Center, University of Minnesota | 3 | 2021-04-02 | 2023-04-03 |
| Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery Oregovomab, Paclitaxel, Carboplatin - Carcinoma, Ovarian Epithelial, Ovarian Neoplasms | Phase 3 | Active not recruiting | CanariaBio Inc. | 615 | 2020-08-25 | 2026-04-01 |
| The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer Survivors Exercise Counseling, Aerobic Exercise, Physiological Support - Ovarian Cancer, Fallopian Tube Adenocarcinoma | Not applicable | Terminated | University of Washington | 64 | 2018-12-05 | 2023-11-29 |
| Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma MCY-M11, Cyclophosphamide - Peritoneal Mesothelioma, Fallopian Tube Adenocarcinoma | Phase 1 | Terminated | MaxCyte, Inc. | 14 | 2018-08-27 | 2021-09-05 |
| Compare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian/Tubal Tissue to Determine Presence of Malignancy Hysteroscopic cell sampling of the fallopian tube - Fallopian Tube Cancer, Ovarian Cancer | Completed | Boston Scientific Corporation | 150 | 2018-08-27 | 2021-01-20 | |
| Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Bevacizumab, Emactuzumab, Laboratory Biomarker Analysis - Fallopian Tube Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 2 | Terminated | M.D. Anderson Cancer Center | 9 | 2017-05-05 | 2024-03-13 |
| Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Biospecimen Collection, Computed Tomography, Echocardiography Test - Acinar Cell Carcinoma, Adenoid Cystic Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 798 | 2017-01-30 | 2026-06-17 |
| Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers Bevacizumab, Laboratory Biomarker Analysis, Nab-paclitaxel - Cervical Adenocarcinoma, Cervical Adenosarcoma | Phase 1 | Completed | Mayo Clinic | 43 | 2014-02-24 | 2024-07-26 |
| Dose Escalation of Cisplatin Hyperthermic Intraperitoneal Chemotherapy After Surgery in Patients With Unresectable Stage IIIC Ovarian, Tube or Peritoneal Primary Adenocarcinoma Cisplatin, Bevacizumab - Ovarian Adenocarcinoma, Fallopian Tube Adenocarcinoma | Phase 1 | Completed | Gustave Roussy, Cancer Campus, Grand Paris | 30 | 2011-06-01 | 2026-08-13 |
| YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis - Fallopian Tube Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma | Terminated | Gynecologic Oncology Group | 2500 | 2007-09-01 | 2018-05-22 |
Ovarian Neoplasms (6) · Fallopian Tube Neoplasms (4) · Brenner Tumor (3) · Peritoneal Neoplasms (2) · Adenocarcinoma, Bronchiolo-Alveolar (1) · Adenocarcinoma, Mucinous (1) · Adrenocortical Carcinoma (1) · Bile Duct Neoplasms (1) · Carcinoma, Acinar Cell (1) · Carcinoma, Adenoid Cystic (1) · Carcinoma, Basal Cell (1) · Carcinoma, Endometrioid (1) · Carcinoma, Giant Cell (1) · Carcinoma, Ovarian Epithelial (1) · Carcinoma, Transitional Cell (1)
Adnexal Diseases (7) · Endocrine Gland Neoplasms (7) · Endocrine System Diseases (7) · Female Urogenital Diseases (7) · Female Urogenital Diseases and Pregnancy Complications (7) · Genital Diseases (7) · Genital Diseases, Female (7) · Genital Neoplasms, Female (7) · Gonadal Disorders (7) · Neoplasms (7) · Neoplasms by Site (7) · Urogenital Diseases (7) · Urogenital Neoplasms (7) · Ovarian Diseases (6) · Neoplasms by Histologic Type (5)
Bevacizumab (3) · Disulfides (2) · Immunoglobulin G (2) · Paclitaxel (2) · Taxes (2) · 130-nm albumin-bound paclitaxel (1) · Albumin-Bound Paclitaxel (1) · CTLA-4 Antigen (1) · Carboplatin (1) · Cisplatin (1) · Cyclophosphamide (1) · Exercise (1) · Interleukin-2 (1) · Ipilimumab (1) · Magnetic Resonance Spectroscopy (1)
Boston Scientific Corporation (1) · CanariaBio Inc. (1) · Gustave Roussy, Cancer Campus, Grand Paris (1) · Gynecologic Oncology Group (1) · M.D. Anderson Cancer Center (1) · Masonic Cancer Center, University of Minnesota (1) · MaxCyte, Inc. (1) · Mayo Clinic (1) · National Cancer Institute (NCI) (1) · University of Washington (1)
United States (9) · Argentina (1) · Belgium (1) · Brazil (1) · Canada (1) · Chile (1) · Czechia (1) · France (1) · Guam (1) · Hungary (1) · India (1) · Italy (1) · Mexico (1) · South Korea (1) · Spain (1)
Anil K. Sood, MD (1) · Claudio Dansky Ullmann, MD (1) · Katherine Bell-McGuinn (1) · Kathryn Pennington (1) · Matthew S. Block, M.D., Ph.D. (1) · Melissa Geller, MD, MS (1) · Sandip P Patel (1) · Sunil Gupta, MD, FRCPC (1) · Ted L Anderson, MD,PhD,FACOG (1)
PMID 27246305, PMID 31969335, PMID 33362722, PMID 33882143, PMID 34380663, PMID 34716198, PMID 38243705, PMID 38358334, PMID 39067873, PMID 39343510, PMID 39417692, PMID 39583952, PMID 39856213, PMID 40402690, PMID 40588371, PMID 41672597, PMID 41892875, PMID 41995270, PMID 42499790
P01CA111412 (1), R21CA215662 (1), U10CA027469 (1), U10CA180868 (1), U10CA180888 (1)